Skip to content
To the full analysis

Intco Medical Technology Stock: Fair Value

300677.SZ
$7.23Closing price of 20 Nov 2026MEQIRI Score 45 out of 100

The fair value of Intco Medical Technology under our model is $8.00, the price is 10% below.

The fair value is an estimate from our model, not a price target.

Daily figure as of 20 Nov 2026

Valuation Signal

Fairly valued
Price
$7.64
Fair value
$8.00
Gap to fair value
−5%

Closing price of 19 Nov 2026, used by the daily score.

In our model the price counts as cheap below $5.72 and expensive above $13.34 (uncertainty high, based on the price swings of the past year).

Calculated with a cost of equity of 7.9%. At 8.9% the fair value would be $6.63, at 6.9% it would be $9.98.

Where the Number Comes From

Earnings × 30.9
no data
Cash-flow model
$8.00
Fair value (model)
$8.00

From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.

Ten-year cash-flow model: 3 years from analyst estimates, then extrapolated until growth reaches 2.3% (five-year average government bond yield). Discounted at 7.9% (government bond yield 2.3% plus beta 1.09 times a risk premium of 5.2%).

Calculate with your own assumptions

The Calculation Step by Step

With these figures the cash flow model arrives at $8.00 per share: free cash flow for the next ten years, each year discounted to today at 7.9%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.

Calculation as a table
YearFree cash flowSourceDiscount factorPresent value (discounted at 7.9%)
2026−$105.72MEstimate, 3 analysts0.9266−$97.96M
2027$109.47MEstimate, 3 analysts0.8585$93.99M
2028$264.39MEstimate, 3 analysts0.7955$210.32M
2029$294.75Mextrapolated at 11.5%0.7371$217.26M
2030$320.48Mextrapolated at 8.7%0.6830$218.88M
2031$342.29Mextrapolated at 6.8%0.6328$216.61M
2032$360.96Mextrapolated at 5.5%0.5864$211.66M
2033$377.25Mextrapolated at 4.5%0.5433$204.97M
2034$391.78Mextrapolated at 3.9%0.5034$197.24M
2035$405.06Mextrapolated at 3.4%0.4665$188.95M
StepValue
Sum of present values (ten years)$1.66B
Terminal value: cash flow 2035 × (1 + 2.3%) / (7.9% − 2.3%)$7.38B
Present value of terminal value (× 0.4665)$3.44B
Equity value (sum plus present value of terminal value)$5.11B
Shares (diluted)637.94M
Value per share (equity value divided by shares)$8.00
Fair value (from the cash flow model alone)$8.00

In the years with estimates, the model derives free cash flow from estimated earnings and revenue, because there are no estimates for the cash flow itself. The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.